Dermatology Appeals: Biologics and Beyond - March 2026

Dermatology appeals have become significantly more complex since biologics became a cornerstone of treatment, and frankly, it's only getting more challenging as we head into 2026. I've been watching practices struggle with denials for these high-cost medications, often leaving patients in limbo while their skin conditions worsen. The good news? There are proven strategies that can dramatically improve your approval rates if you know what payers are really looking for.

Understanding the Current Biologics Landscape in Dermatology

The biologics market has exploded over the past few years, with newer agents like risankizumab and bimekizumab joining established players like adalimumab and secukinumab. But here's what's really happening behind the scenes: payers are getting pickier, not because these drugs don't work, but because they're trying to manage costs while ensuring appropriate utilization.

Most insurance companies now require what I call the "failure ladder" – patients must try and fail topical treatments, phototherapy, and often methotrexate before they'll even consider biologics. This isn't necessarily bad medicine, but it creates documentation headaches for your practice.

What's changed recently is that payers are also looking more closely at specific indications. A psoriasis approval pathway looks different from an atopic dermatitis one, and the documentation requirements can vary significantly. I've seen practices get tripped up because they're using a one-size-fits-all approach to their prior authorization requests.

Documentation That Actually Gets Approvals

Let me be blunt: most practices are terrible at biologic documentation. You need to paint a complete picture of patient suffering and treatment failure, not just check boxes. Here's what actually moves the needle:

Disease severity scores are non-negotiable. Use BSA (Body Surface Area), PASI scores for psoriasis, or EASI scores for atopic dermatitis. But don't just record numbers – document how these scores impact daily life. "Patient reports inability to sleep due to pruritus, missing work 2-3 days per month" carries more weight than you'd think.

Previous treatment documentation needs to be bulletproof. For each failed therapy, include the specific medication, dosage, duration of treatment, and reason for discontinuation. "Patient tried topical steroids" won't cut it anymore. You need "Patient used clobetasol propionate 0.05% ointment twice daily for 6 weeks with less than 25% improvement in lesions, discontinued due to skin atrophy concerns."

Photos are your secret weapon. I know not every practice has a great photo system, but visual documentation of disease severity can make or break an appeal. Before and after shots showing treatment failure are particularly powerful.

Common Denial Reasons and How to Prevent Them

After reviewing hundreds of dermatology denials, I've noticed patterns that are completely avoidable with better upfront preparation.

Medical necessity denials usually stem from inadequate documentation of disease severity or functional impact. Payers want to see that the condition significantly affects quality of life and that conventional treatments have genuinely failed. A patient with mild psoriasis affecting only elbows isn't getting approved for a $5,000/month biologic, no matter how well you write the appeal.

Step therapy violations are probably the most frustrating because they often involve treatments that clearly aren't appropriate for the patient's situation. The key is documenting contraindications or previous failures thoroughly. If your patient can't use methotrexate due to liver disease, make sure that's prominent in every piece of documentation.

Dosing and frequency issues have become more common as payers scrutinize maintenance regimens. Some patients do need more frequent dosing than the standard protocol, but you need robust documentation showing inadequate response to standard dosing before they'll approve it.

Crafting Winning Appeals

When you do get a denial, your appeal strategy matters more than you might think. I've seen identical cases with opposite outcomes based purely on how the appeal was presented.

Start with a compelling clinical narrative. Lead with the patient's story – how long they've suffered, what they've tried, how the condition affects their work or family life. Then methodically address each reason for denial with specific evidence. If they're questioning medical necessity, provide detailed severity scores and functional assessments. If it's a step therapy issue, create a clear timeline of previous treatments and failures.

Use peer-reviewed literature strategically. Don't just attach random studies – find research that specifically supports your patient's situation. A study showing superior outcomes for your chosen biologic in patients who failed methotrexate can be incredibly persuasive.

Consider getting the dermatologist on the phone. Peer-to-peer reviews aren't always successful, but when they work, they can resolve complex cases quickly. The key is making sure your physician is prepared with specific patient details and can articulate why this particular treatment is medically necessary.

Leveraging Technology and Resources

The appeal process has gotten complex enough that many practices are turning to technology solutions. AI-powered appeal generators can help ensure you're hitting all the key points and using language that resonates with payers. These tools aren't magic bullets, but they can significantly reduce the time your staff spends crafting appeals while improving consistency.

Don't overlook manufacturer support programs either. Most biologic companies have patient assistance programs and can provide appeal letter templates specific to their medications. Some even have staff who can help with prior authorization calls.

Keep an appeals database. Track what works and what doesn't for different payers. You'll start to notice patterns – certain insurance companies consistently deny specific combinations, or particular documentation approaches work better with different payers.

Moving Forward: Building a Sustainable Strategy

Success with dermatology appeals isn't about fighting every denial – it's about preventing denials through better upfront processes and knowing when to appeal versus when to try alternative approaches.

Start by auditing your current prior authorization success rates. If you're getting approved less than 70% of the time on initial submissions, you've got documentation issues that need addressing. Work with your dermatologists to standardize how they document disease severity and treatment failures.

Create templates for common scenarios, but make sure your staff understands they're starting points, not fill-in-the-blank forms. Every patient's story is different, and cookie-cutter approaches are increasingly obvious to payers.

Finally, stay informed about changing payer policies. What worked last year might not work today, and being proactive about policy changes can save you significant time and frustration. The landscape will keep evolving, but practices that master these fundamentals will stay ahead of the curve.